P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY

• L. E. Roeker,
• A. R. Mato,
• J. R. Brown,
• C. C. Coombs,
• N. N. Shah,
• W. G. Wierda,
• M. R. Patel,
• K. L. Lewis,
• M. Balbas,
• J. Zhao,
• N. C. Ku,
• J. F. Kherani,
• D. E. Tsai,
• B. Nair,
• C. Y. Cheah

Affiliations

L. E. Roeker

1 Memorial Sloan Kettering Cancer Center, New York

A. R. Mato

1 Memorial Sloan Kettering Cancer Center, New York

J. R. Brown

2 Dana-Farber Cancer Institute and Harvard Medical School, Boston

C. C. Coombs

3 University of North Carolina at Chapel Hill, Chapel Hill

N. N. Shah

4 Medical College of Wisconsin, Milwaukee

W. G. Wierda

5 MD Anderson Cancer Center, Houston

M. R. Patel

6 Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, United States of America

K. L. Lewis

7 Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

M. Balbas

8 Loxo Oncology at Lilly, Stamford, United States of America

J. Zhao

8 Loxo Oncology at Lilly, Stamford, United States of America

N. C. Ku

8 Loxo Oncology at Lilly, Stamford, United States of America

J. F. Kherani

8 Loxo Oncology at Lilly, Stamford, United States of America

D. E. Tsai

8 Loxo Oncology at Lilly, Stamford, United States of America

B. Nair

8 Loxo Oncology at Lilly, Stamford, United States of America

C. Y. Cheah

7 Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia